QuidelOrtho (QDEL): Assessing Valuation After FY2025 Guidance and Q3 Earnings Reveal Growing Net Loss

QuidelOrtho (QDEL) released its fiscal 2025 financial guidance along with reporting third quarter earnings, giving investors a fresh look at both the company’s expectations and its recent financial performance. This dual update is important for anyone tracking the stock.

See our latest analysis for QuidelOrtho.

QuidelOrtho’s latest guidance and earnings release came as the share price continues a tough run, falling nearly 25% over the last month and down more than 50% year-to-date. Even with the new outlook on revenues, the one-year total shareholder return sits at -44.8% and the longer-term picture remains challenging as momentum has been fading while investors weigh ongoing losses against hopes for a turnaround.

If this earnings season has you searching for new opportunities, now is a great time to explore the healthcare sector with our carefully curated See the full list for free.

With shares trading at a steep discount and losses mounting, the question facing investors is whether QuidelOrtho’s valuations now offer a compelling entry point or if the market is already reflecting all risks and potential for future growth.

Most Popular Narrative: 43.5% Undervalued

Simply Wall St’s widely followed narrative arrives at a fair value of $37.67 per share versus the last close of $21.28. This suggests significant upside if the narrative plays out as projected. This disparity sets the stage for a closer look at what is driving this optimistic outlook.

Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform address the trend toward fast, decentralized testing and are likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.

Read the complete narrative.

What assumptions make this narrative so bullish? The numbers hinge on future leaps in margins, rapid market expansion, and a surprisingly aggressive earnings comeback. Want to discover which forecasts turn this projection into a bold claim? Dive in for the full breakdown.

Result: Fair Value of $37.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent declines in COVID-related revenues and risks from product discontinuations could limit QuidelOrtho's ability to fully realize its recovery narrative.

Find out about the key risks to this QuidelOrtho narrative.

Build Your Own QuidelOrtho Narrative

If the current outlook does not align with your views or you'd rather analyze the numbers yourself, you have the tools to build your own perspective in just a few minutes, your way. Do it your way

A great starting point for your QuidelOrtho research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Seize your next big opportunity by searching beyond the obvious. These handpicked ideas can help you get ahead of the crowd in today’s market.

• Unlock the growth potential of artificial intelligence by starting with these 27 AI penny stocks. Explore companies making waves in machine learning, automation, and smart technology.
• Consider the chance for stable income streams by checking out these 18 dividend stocks with yields > 3% with impressive yields and a record of consistent payouts.
• Accelerate your portfolio’s edge with these 81 cryptocurrency and blockchain stocks at the forefront of blockchain innovation, digital assets, and the changing world of decentralized finance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com